You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

100 Results
Guidelines and Advice
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - In Combination with Chemotherapy for Refractory Follicular Lymphoma
ODB - General Benefit
    chlorambucil
Dec 2018
Drug
Other Name(s): Alunbrig®
Jul 2024
Guidelines and Advice
Guidelines and Advice
Status: Current
ID: N/A
Version: 1
Nov 2018
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
Exceptional Access Program
    brigatinib - For the treatment of anaplastic lymphoma kinase-positive locally advanced or metastatic non-small cell lung cancer according to clinical criteria
Jul 2024
Guidelines and Advice
Status: Current
ID: PET 19
Version: n/a
Nov 2018

Pages